Immunology: Guide the immunology drug discovery lifecycle with ‘omics...

tv.qiagenbioinformatics.com · May 5, 2026 · 57m

The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These biologics generate billions in annual revenue, but when exclusivity ends, competition from biosimilars quickly becomes a concern.

Using the real-world example of Stelara, which faced multiple new biosimilars within a year of its patent expiry, we explore how to sustain value with smarter lifecycle strategy. We’ll combine data curation, large-scale ‘omics…